National rank
#7
Position in the 2026 American CEO Performance Ranking.
CEO & company research profile · Reviewed 2026-09-13
David Ricks: Eli Lilly
David Ricks ranks #7 in the 2026 American CEO Performance Ranking with a Meridian score of 84.1. This expanded profile shows the operating record, strategic case, risk factors and category scores behind that result.
Meridian score
84.1 / 100
Composite score using the common seven-factor Meridian framework.
Company
Eli Lilly
A nationally significant listed company included in the 2026 research universe.
Leadership tenure
Eli Lilly CEO since January 2017
Tenure is considered when deciding how much operating evidence can reasonably be attributed to the current CEO.
Operating record
2025 performance snapshot
Lilly's growth has been transformed by diabetes and obesity medicines, with demand driving rapid revenue expansion and unprecedented manufacturing investment.
Exceptional medicines growth and manufacturing expansion score strongly, moderated by concentration and execution risk around capacity.
Seven-factor score breakdown
| Factor | Weight | Score |
|---|---|---|
| Shareholder performance | 25% | 89 / 100 |
| Revenue & earnings | 20% | 96 / 100 |
| Capital efficiency | 15% | 86 / 100 |
| Strategic execution | 15% | 92 / 100 |
| Innovation & future investment | 10% | 95 / 100 |
| Workforce signal | 10% | 85 / 100 |
| Governance | 5% | 86 / 100 |
Category scores are editorial-data assessments based on the published methodology and available public evidence. They are designed for comparative research, not investment advice.
Strategic assessment
Strategic execution
Convert scientific leadership in metabolic disease into durable global franchises while broadening the pipeline across oncology, neuroscience and immunology.
Capital allocation
Large manufacturing commitments are being made ahead of demand, raising execution risk but also supporting long-duration capacity growth.
Innovation and future investment
R&D productivity and clinical execution are core to the investment case, with pipeline quality carrying more weight than conventional technology spending.
Workforce and operating model
The expansion requires major hiring in manufacturing, research and technical operations, particularly around new production capacity.
What could change the ranking
Risks and counterweights
Product concentration, reimbursement policy, competitive pipelines and manufacturing execution temper the otherwise exceptional growth profile.
Future editions can move the score materially when annual results, acquisitions, capital-allocation decisions, management changes, regulatory events or significant governance developments alter the evidence base.
View the primary or investor source used for this profile.
Meridian uses annual reports, official results, filings and attributable investor disclosures as the primary evidence layer. Comparative scores are versioned and may change as new evidence becomes available.